Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3830-3840

  Li, Yafei ^a,b   Sun, Zhifu ^a   Cunningham, Julie M ^a   Aubry, Marie C ^a   Wampfler, Jason A ^a   Croghan, Gary A ^a   Johnson, Cassandra ^a   Wu, Danli ^a   Aakre, Jeremiah A ^a   Molina, Julian ^a   Wang, Liewei ^a   Pankratz, V Shane ^a   Yang, Ping ^a  

^a MAYO CLINIC   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; GPX5 GENE; GPX7 GENE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NRAS GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RAF1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; DEOXYCYTIDINE; DNA REPAIR; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; LUNG NEOPLASMS; MALE; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 79957881945     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2877     Document Type: Article

References (50)

1. Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs 2008;12:587-96.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92. (Pubitemid 38101633)
3. Moore DJ, Lee J. In: Pass H, Mitchell J, Johnson D, Turrisi AT (editors). Lung Cancer: Principles and Practice. Philadelphia: Lipincott-Raven Publishers; 1996. p. 495-509.
4. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006;24:1761-9. (Pubitemid 46622148)
5. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:118-23.
6. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601. (Pubitemid 41103746)
7. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in nonsmall- cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-6. (Pubitemid 38609439)
8. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203. (Pubitemid 39199306)
9. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-43. (Pubitemid 39099767)
10. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008;18:955-65.
11. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004;9 Suppl 2:3-8. (Pubitemid 38747838)
12. Zhao J, Kim JE, Reed E, Li QQ. Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol 2005;27: 247-56.
13. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
14. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10: 136-43. (Pubitemid 38114172)
15. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005;5:124-31.
16. Yang P, Bamlet WR, Sun Z, Ebbert JO, Aubry MC, Krowka MJ, et al. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005;128:445-52. (Pubitemid 40994509)
17. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008;168:1097-103. (Pubitemid 351749227)
18. Yang P, Wentzlaff KA, Katzmann JA, Marks RS, Allen MS, Lesnick TG, et al. Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:461-5. (Pubitemid 29230552)
19. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001;29:233-7. (Pubitemid 32952665)
20. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-20. (Pubitemid 38085242)
21. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004;429: 446-52. (Pubitemid 38715138)
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
23. Njalsson R, Ristoff E, Carlsson K, Winkler A, Larsson A, Norgren S. Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 2005; 116:384-9. (Pubitemid 40521115)
24. Sun Z, Chen J, Aakre J, Marks RS, Garces YY, Jiang R, et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010;21:2011-6.
25. Witowsky JA, Johnson GL. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J Biol Chem 2003;278:1403-6. (Pubitemid 36801363)
26. Xu S, Cobb MH. MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases. J Biol Chem 1997;272: 32056-60. (Pubitemid 28011874)
27. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene 1998;17:1457-62. (Pubitemid 28458413)
28. Beeram M, Patnaik A, Rowinsky EK. Regulation of c-Raf-1: therapeutic implications. Clin Adv Hematol Oncol 2003;1:476-81.
29. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993;364:249-52. (Pubitemid 23257085)
30. Cornwell MM, Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 1993;268:15347-50. (Pubitemid 23222019)
31. Stanton VP Jr, Cooper GM. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 1987;7:1171-9. (Pubitemid 17017439)
32. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997;9:174-9. (Pubitemid 27135984)
33. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/ MEK/ERK pathway by protein interactions. Biochem J 2000;351: 289-305.
34. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 2000;11:185-90. (Pubitemid 30211007)
35. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998;101:153-9. (Pubitemid 28058914)
36. McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001;85: 1753-8. (Pubitemid 34081523)
37. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999;31:261-72. (Pubitemid 29452853)
38. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, et al. Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem 2003;384:567-74. (Pubitemid 36609172)
39. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213-32. (Pubitemid 35307152)
40. Vernet P, Rock E, Mazur A, Rayssiguier Y, Dufaure JP, Drevet JR. Selenium-independent epididymis-restricted glutathione peroxidase 5 protein (GPX5) can back up failing Se-dependent GPXs in mice subjected to selenium deficiency. Mol Reprod Dev 1999;54: 362-70. (Pubitemid 29519865)
41. Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, et al. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol 2009;4:479-85.
42. Zhao H, Liang D, Grossman HB, Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 2005;66:769-74. (Pubitemid 41440822)
43. Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, et al. Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells. J Biol Chem 2004;279:43522-9. (Pubitemid 39390652)
44. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007;25: 3015-23. (Pubitemid 47218047)
45. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009;1790:1555-68.
46. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
47. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
48. Bartram CR, Ludwig WD, Hiddemann W, Lyons J, Buschle M, Ritter J, et al. Acute myeloid leukemia: analysis of ras gene mutations and clonality definedbypolymorphic X-linkedloci. Leukemia1989;3:247-56.
49. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102:285-90.
50. Karimianpour N, Mousavi-Shafaei P, Ziaee AA, Akbari MT, Pourmand G, Abedi A, et al. Mutations of RAS gene family in specimens of bladder cancer. Urol J 2008;5:237-42.